Active Ingredient(s): Palifermin
FDA Approved: * December 15, 2004
Pharm Company: * AMGEN
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Kepivance Overview

Palifermin (trade name Kepivance, marketed by Biovitrum) is a truncated human recombinant keratinocyte growth factor (KGF)[1] produced in Escherichia coli. KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract.[2] Contents 1 Therapeutic use(s) 2 Drug target/mechanism of action 3 Side effects 4 Administration 5 Drug interactions 6 Pre-clinical trials 6.1 Toxicology studies 7 Clinical trials 7.1 Phase I 7.2 Phase II 7.3...

Read more Kepivance Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Kepivance Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Injection: 6.25mg, 60mcg/kg/day
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Kepivance: (1 result)

Sorted by National Drug Code
  • 66658-112 Kepivance 6.25 mg/1.2ml Intravenous Injection, Powder, Lyophilized, for Solution by Swedish Orphan Biovitrum Ab (Publ)

Other drugs which contain Palifermin or a similar ingredient: (1 result)